|
Orthologous residues
|
|
HDAC5 (human): S259‑p, HDAC5 (mouse): S250‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
mutation of modification site, phospho-antibody, western blotting
|
|
Relevant cell lines - cell types - tissues:
BAEC (endothelial)
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
cow
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
KINASE
|
PKD1 (human)
|
activation of upstream enzyme, transfection of wild-type enzyme, phospho-antibody, siRNA inhibition of enzyme, transfection of inactive enzyme
|
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
VEGF
|
|
|
|
increase
|
|
|
U73122
|
VEGF
|
|
|
inhibit treatment-induced decrease
|
|
|
LY294002
|
VEGF
|
|
|
no effect upon treatment-induced increase
|
|
|
GF109203X
|
VEGF
|
|
|
inhibit treatment-induced increase
|
|
|
Ro31-8425
|
VEGF
|
|
|
inhibit treatment-induced increase
|
|
|
Go 6976
|
VEGF
|
|
|
inhibit treatment-induced increase
|
|
|
|
Downstream Regulation
|
|
Effect of modification (function):
intracellular localization
|
|
Effect of modification (process):
cell motility, altered, transcription, altered
|
|
Comments:
required for VEGF-induced nuclear export, transcription of MEF2 and in vitro angiogenesis
|